微创与经心尖及经股动脉主动脉瓣植入术:一对一倾向性评分匹配分析
该单中心研究连续纳入2009年7月至2017年7月接受微创主动脉瓣置换术(1929例)、经心尖(607例)和经股动脉(1273例)主动脉瓣植入术的患者,按23项术前危险因素进行1:1:1倾向性评分匹配,得到177个三 triplet(n=531)。匹配后三组30天死亡率、卒中和心肌梗死无显著差异,经心尖组重症监护和住院时间显著更长;中期生存方面经心尖组较微创组有不利趋势但无显著差异。
要点
- 匹配后30天死亡率微创组2.3%、经心尖组4.5%、经股动脉组1.7%,无显著差异(P=.34)。
- 经心尖组重症监护和住院时间均显著长于其他两组。
- 中期生存经心尖组较微创组有不利趋势(HR 1.48,95%CI 0.95-2.31,P=.17),三组间无显著差异。
核心结论
- 在中危患者的真实世界倾向性评分匹配队列中,微创主动脉瓣置换术、经心尖和经股动脉主动脉瓣植入术的早期死亡率无显著差异,但围术期并发症发生率因入路不同而异。
- 随访期间经心尖组生存结局较微创组有不利趋势,但三组间无显著差异。
研究设计与样本
- 单中心连续纳入2009年7月至2017年7月接受微创主动脉瓣置换术(n=1929)、经心尖(n=607)和经股动脉(n=1273)主动脉瓣植入术的患者。
- 按23项术前危险因素进行1:1:1倾向性评分匹配,得到177个三 triplet(n=531)。
主要发现
- 匹配后中位欧洲心脏手术风险评估系统II评分分别为微创组3.0%、经心尖组3.4%、经股动脉组2.9%,胸外科医师协会预测死亡风险分别为3.2%、3.6%、3.4%。
- 30天死亡率:微创组2.3% vs 经心尖组4.5% vs 经股动脉组1.7%(P=.34),无显著差异。
- 卒中:微创组1.1% vs 经心尖组0.6% vs 经股动脉组1.7%(P=.84),无显著差异。
- 心肌梗死:微创组0.6% vs 经心尖组0.0% vs 经股动脉组0.0%(P=.83),无显著差异。
- 经心尖组重症监护时间和住院时间均显著长于其他两组。
关键数值与推荐
- 围术期并发症按瓣膜学术研究联盟2标准定义。
- 匹配后三组30天死亡率、卒中和心肌梗死均无显著差异(P值分别为.34、.84、.83)。
- 经心尖组重症监护和住院时间显著更长。
- 经心尖组中期生存较微创组有不利趋势(HR 1.48,95%CI 0.95-2.31,P=.17)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Although transcatheter aortic valve implantation was the treatment of choice in inoperable and high-risk patients, the effect of transcatheter aortic valve implantation relative to conventional aortic valve replacement via ministernotomy in patients with moderate surgical risk remains unclear. METHODS: We consecutively enrolled patients who underwent minimally invasive aortic valve replacements via ministernotomy (n = 1929), transapical (n = 607), and transfemoral (n = 1273) aortic valve implantations from a single center during the period from July 2009 to July 2017. Of those, we conducted a 1:1:1 propensity score matching according to 23 preoperative risk factors. RESULTS: We were able to find 177 triplets (n = 531). The median European System for Cardiac Operative Risk Evaluation II was 3.0% versus 3.4% versus 2.9%, and Society of Thoracic Surgeons Predicted Risk of Mortality was 3.2% versus 3.6% versus 3.4%, respectively. According to the Valve Academic Research Consortium 2 criteria, there were no significant periprocedural differences regarding 30-day mortality (2.3% minimally invasive aortic valve replacement vs 4.5% transapical transcatheter aortic valve implantation vs 1.7% transfemoral transcatheter aortic valve implantation, P = .34), stroke (1.1% minimally invasive aortic valve replacement vs 0.6% transapical transcatheter aortic valve implantation vs 1.7% transfemoral transcatheter aortic valve implantation, P = .84), or myocardial infarction (0.6% minimally invasive aortic valve replacement vs 0.0% transapical transcatheter aortic valve implantation vs 0.0% transfemoral transcatheter aortic valve implantation, P = .83). Both intensive care and hospitalization times were significantly longer in the transapical group. Regarding midterm survival, transapical transcatheter aortic valve implantation was associated with a tendency toward a less favorable outcome (hazard ratio, 1.48; 95% confidence interval, 0.95-2.31; P = .17) compared with minimally invasive aortic valve replacement. CONCLUSIONS: In this real-world propensity score-matched minimally invasive aortic valve replacement, transapical transcatheter aortic valve implantation, transfemoral transcatheter aortic valve implantation cohort of intermediate-risk patients, early mortality was not significantly different, whereas the rates of periprocedural complications were different depending on the approach. During follow-up, there was a tendency in the transapical transcatheter aortic valve implantation group toward a less favorable survival outcome, although there was no significant difference among the 3 groups.
引用
- Furukawa N, Kuss O, Emmel E, et al. Minimally invasive versus transapical versus transfemoral aortic valve implantation: A one-to-one-to-one propensity score-matched analysis. J Thorac Cardiovasc Surg. 2018. PMID: 29861110. doi:10.1016/j.jtcvs.2018.04.104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。